Is Allovir Stock a Good Investment?
Allovir Investment Advice | ALVR |
- Examine Allovir's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Allovir's leadership team and their track record. Good management can help Allovir navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Allovir's business and its evolving consumer preferences.
- Compare Allovir's performance and market position to its competitors. Analyze how Allovir is positioned in terms of product offerings, innovation, and market share.
- Check if Allovir pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Allovir's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Allovir stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Allovir is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Allovir Stock
Researching Allovir's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 49.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allovir recorded a loss per share of 0.9. The entity had not issued any dividends in recent years. The firm had 1:10 split on the April 2, 2013.
To determine if Allovir is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Allovir's research are outlined below:
| Allovir generated a negative expected return over the last 90 days | |
| Allovir has high historical volatility and very poor performance | |
| Allovir has some characteristics of a very speculative penny stock | |
| Allovir has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (190.42 M) with profit before overhead, payroll, taxes, and interest of 165 K. | |
| Allovir currently holds about 172.67 M in cash with (124.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Allovir has a poor financial position based on the latest SEC disclosures | |
| Roughly 49.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Allovir stock touches 52-week low at 0.47 amid market challenges - Investing.com |
Allovir uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Allovir. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allovir's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Allovir's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Allovir's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-05 | 2024-06-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2024-11-01 | 2024-09-30 | -0.09 | -0.0358 | 0.0542 | 60 | ||
2024-03-15 | 2023-12-31 | -0.43 | -0.36 | 0.07 | 16 | ||
2021-02-11 | 2020-12-31 | -0.42 | -0.34 | 0.08 | 19 | ||
2024-05-13 | 2024-03-31 | -0.16 | -0.26 | -0.1 | 62 | ||
2021-05-06 | 2021-03-31 | -0.4 | -0.5 | -0.1 | 25 | ||
2022-05-05 | 2022-03-31 | -0.8 | -0.69 | 0.11 | 13 | ||
2022-02-10 | 2021-12-31 | -0.81 | -0.92 | -0.11 | 13 |
Know Allovir's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Allovir is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allovir backward and forwards among themselves. Allovir's institutional investor refers to the entity that pools money to purchase Allovir's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rbf Llc | 2024-09-30 | 449 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 324.7 K | Fmr Inc | 2024-09-30 | 310.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 296.5 K | Two Sigma Investments Llc | 2024-09-30 | 295.2 K | State Street Corp | 2024-09-30 | 222.4 K | Commonwealth Equity Services Inc | 2024-09-30 | 201 K | Marquette Asset Management Inc. | 2024-09-30 | 178.9 K | Jane Street Group Llc | 2024-06-30 | 173 K | Ecor1 Capital, Llc | 2024-09-30 | 11.3 M | Octagon Capital Advisors Lp | 2024-09-30 | 11.2 M |
Allovir's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.25 M.Market Cap |
|
Allovir's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.00) | (0.95) | |
| Return On Capital Employed | (1.12) | (1.17) | |
| Return On Assets | (1.00) | (0.95) | |
| Return On Equity | (1.31) | (1.24) |
Determining Allovir's profitability involves analyzing its financial statements and using various financial metrics to determine if Allovir is a good buy. For example, gross profit margin measures Allovir's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Allovir's profitability and make more informed investment decisions.
Evaluate Allovir's management efficiency
Allovir has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/15/2024, Return On Tangible Assets is likely to grow to -0.95. In addition to that, Return On Capital Employed is likely to drop to -1.17. At this time, Allovir's Total Assets are relatively stable compared to the past year. As of 12/15/2024, Other Current Assets is likely to grow to about 5.1 M, while Non Current Assets Total are likely to drop slightly above 3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.40 | 2.59 | |
| Tangible Book Value Per Share | 1.40 | 2.59 | |
| Enterprise Value Over EBITDA | (0.04) | (0.04) | |
| Price Book Value Ratio | 0.49 | 0.51 | |
| Enterprise Value Multiple | (0.04) | (0.04) | |
| Price Fair Value | 0.49 | 0.51 | |
| Enterprise Value | 8 M | 7.6 M |
The leadership approach at Allovir's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.741 |
Basic technical analysis of Allovir Stock
As of the 15th of December 2024, Allovir shows the Standard Deviation of 7.08, risk adjusted performance of (0.04), and Mean Deviation of 3.96. Allovir technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Allovir standard deviation and potential upside to decide if Allovir is priced correctly, providing market reflects its regular price of 0.45 per share. As Allovir is a penny stock we also strongly suggest to validate its jensen alpha numbers.Allovir's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allovir insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allovir's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allovir insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allovir's Outstanding Corporate Bonds
Allovir issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Allovir uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Allovir bonds can be classified according to their maturity, which is the date when Allovir has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Allovir's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Allovir's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 3.96 | |||
| Coefficient Of Variation | (1,472) | |||
| Standard Deviation | 7.08 | |||
| Variance | 50.19 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.37) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 47.97 | |||
| Value At Risk | (8.24) | |||
| Potential Upside | 6.25 | |||
| Skewness | (2.56) | |||
| Kurtosis | 13.1 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 3.96 | |||
| Coefficient Of Variation | (1,472) | |||
| Standard Deviation | 7.08 | |||
| Variance | 50.19 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.37) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 47.97 | |||
| Value At Risk | (8.24) | |||
| Potential Upside | 6.25 | |||
| Skewness | (2.56) | |||
| Kurtosis | 13.1 |
Consider Allovir's intraday indicators
Allovir intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Allovir stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Allovir time-series forecasting models is one of many Allovir's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allovir's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Allovir Stock media impact
Far too much social signal, news, headlines, and media speculation about Allovir that are available to investors today. That information is available publicly through Allovir media outlets and privately through word of mouth or via Allovir internal channels. However, regardless of the origin, that massive amount of Allovir data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Allovir news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Allovir relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Allovir's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Allovir alpha.
Allovir Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Allovir can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Allovir Corporate Management
| Sonia Choi | Senior Relations | Profile | |
| Agustin MD | Advisor | Profile | |
| Dana MBA | VP Operations | Profile | |
| Ann Leen | Chief Officer | Profile | |
| Cintia PharmD | Chief Officer | Profile | |
| David Hallal | Executive Board | Profile | |
| Jeroen Beek | Consultant | Profile |
Already Invested in Allovir?
The danger of trading Allovir is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allovir is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allovir. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allovir is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.